RUNX1 and cancer: Interestingly, we observed a lower expression of cleaved PARP-1 and ARP2/3 in the hepatocytes of metastatic lesions that were generated from RUNX1-deficient HT29 cancer cells in comparison to those that were generated by control HT29 cancer cells (Figure 6a).